RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.

Glen Rock, N.J., April 03, 2023 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the publication of four articles describing the pharmacological activity of novel structural analogs of KRM-II-81, the Company’s lead GABAkine. Like KRM-II-81, these analogs enhance GABAergic neurotransmission and function as orally-bioavailable anti-seizure agents in the absence of the sedation typically associated with GABA augmentation. KRM-II-81, itself, has been shown to be effective across a broad array of anti-seizure models including those predicting efficacy in patients that are pharmaco-resistant and in brain tissue from epilepsy patients who are no longer treatable with drugs. In addition KRM-II-81 is active in relieving acute, chronic, and neuropathic pain in a number of models without developing tolerance or producing sedation.

Read more at globenewswire.com